Revance Therapeutics (NASDAQ:RVNC) Posts Earnings Results, Beats Estimates By $0.01 EPS

Revance Therapeutics (NASDAQ:RVNC) posted its quarterly earnings data on Sunday. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.25) by $0.01, MarketWatch Earnings reports. Revance Therapeutics had a negative return on equity of 85.72% and a negative net margin of 5,818.87%.

NASDAQ:RVNC traded down $1.52 during mid-day trading on Tuesday, reaching $25.44. 33,228 shares of the company’s stock traded hands, compared to its average volume of 425,713. Revance Therapeutics has a 12-month low of $11.78 and a 12-month high of $34.62. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -5.70 and a beta of 1.42. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.07 and a quick ratio of 7.01. The company has a 50 day moving average price of $28.31 and a 200-day moving average price of $26.92.

RVNC has been the subject of several research analyst reports. Mizuho lifted their price objective on Revance Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $35.00 price target (up previously from $33.00) on shares of Revance Therapeutics in a research report on Tuesday. Needham & Company LLC raised their price target on Revance Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, January 8th. Barclays raised their price target on Revance Therapeutics from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Monday, October 26th. Finally, Zacks Investment Research downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Revance Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $32.88.

In related news, insider Aubrey Rankin sold 33,119 shares of the business’s stock in a transaction dated Monday, November 30th. The stock was sold at an average price of $23.85, for a total transaction of $789,888.15. Following the transaction, the insider now owns 67,871 shares in the company, valued at approximately $1,618,723.35. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.80% of the stock is owned by insiders.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.

Read More: Should You Consider an Index Fund?

Earnings History for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.